Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02307604 : SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial Access
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Pathologically confirmed newly diagnosed primary CNS tumors, with a focus on diffuse
gliomas of grades II, III and IV, meningiomas from patients who are candidates for
pharmacotherapy, and rare CNS tumors;

- Availability of adequate Human Biological Material (HBM): FFPE tissue sample from the
primary and/or recurrent tumor and/or metastasis, obtained at the time of surgery or
biopsy; minimal amount requested is detailed in the HBM guidelines. Inclusion of
samples taken at any recurrence diagnosed during follow-up is strongly encouraged but

- At least three months life expectancy;

- Written informed consent according to ICH/GCP and national/local regulations;

- Absence of exclusion criteria, such as active hepatitis B/C or HIV, second
malignancies, severe organ dysfunction, or other comorbidities that will prevent
inclusion into clinical trials.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557